Editas Sells Vertex License Fees to DRI for $57M to Fund Gene Editing Pipeline

Editas Medicine has entered into an agreement with DRI Healthcare Trust, selling its future license fees and payments from Vertex Pharmaceuticals for $57 million upfront. Under this deal, DRI will receive up to 100% of future annual license fees from Vertex, ranging from $5 million to $40 million, as well as a portion of a $50 million contingent payment[1][2]. This strategic move provides Editas with the necessary funds to advance its gene editing pipeline, focusing on therapies for sickle cell disease and beta-thalassemia[1]. The deal highlights Editas' efforts to enhance financial stability amid recent changes and challenges, including clinical delays and patent disputes[1][2].